Real-World Characteristics and Treatment Patterns in Patients with Urticaria Initiating Omalizumab in the United States

BACKGROUND: Omalizumab is indicated for the management of chronic idiopathic urticaria (CIU) in patients aged 12 years or older with persistent hives that are not adequately controlled by H1 antihistamines. While its safety and efficacy in CIU patients have been evaluated in multiple clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Ke, Xuehua, Kavati, Abhishek, Wertz, Debra, Huang, Qing, Wang, Liya, Willey, Vincent J., Stephenson, Judith J., Ortiz, Benjamin, Paknis, Brandee, Bernstein, Jonathan A., Beck, Lisa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397740/
https://www.ncbi.nlm.nih.gov/pubmed/29952712
http://dx.doi.org/10.18553/jmcp.2018.24.7.598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397740/
https://www.ncbi.nlm.nih.gov/pubmed/29952712
http://dx.doi.org/10.18553/jmcp.2018.24.7.598

Ejemplares similares